摘要: |
目的比较急性冠脉综合征患者(ACS)经皮冠状动脉介入术(PCI)后应用替格瑞洛及氯吡格雷治疗的临床效果。方法选取2014年12月至2015年10月在我院心内科住院治疗的诊断为ACS并且拟行PCI治疗的患者124例,随机将患者分为A组和B组,各62例。A组应用阿司匹林+替格瑞洛抗血小板治疗;B组应用阿司匹林+氯吡格雷抗血小板治疗。两组均观察治疗12个月,比较两组临床效果。结果 A组术后2h、24h、7d的血小板聚集率均显著低于B组[(52.24±7.56)vs.(56.82±7.49)、(48.65±7.90)vs.(55.31±7.11)、(42.47±6.30)vs.(53.86±6.55)],差异有统计学意义(P<0.05),A组血小板聚集率达标率高于B组(82.26%vs.41.94%),差异有统计学意义(P<0.05);术后4周A组MACE发生率低于对照组(12.90%vs.30.65%),差异有统计学意义(P<0.05)。结论 ACS患者PCI术后应用替格瑞洛抗血小板聚集优于氯吡格雷,且降低MACE事件发生率。 |
关键词: 急性冠脉综合征 经皮冠状动脉介入术 替格瑞洛 氯吡格雷 |
DOI: |
分类号: |
基金项目: |
|
Comparison of Clinical Efficacy of Ticagrelor and Clopidogrel in Patients with Acute Coronary Syndrome after PCI |
Yang Lixia;Guo Haixia;Dong Li
|
Qinhuangdao First Hospital,Emergency Department
|
Abstract: |
Objective To compare the clinical efficacy of ticagrelor and clopidogrel in patients with acute coronary syndrome( ACS) afterpercutaneous coronary intervention( PCI). Methods 124 patients that was diagnosedwith ACS and planned to be treated with PCI in our cardiologydepartment from December 2014 to October 2015 were selected,they were randomly divided into group A and group B,each with 62 cases. Group A was treated with aspirin and ticagrelor antiplatelet therapyand group Bwas treated with aspirin and clopidogrel antiplatelet therapy. Two groups were observed for 12 months,and the clinical effect of the two groups were compared. Results Platelet aggregation rate 2 h,24 h,7 d after oprtation of A group were all significantly lower than that of B Group[( 52. 24 ± 7. 56) vs.( 56. 82 ± 7. 49),( 48. 6 ± 57. 90) vs.( 55. 31 ± 7. 11),( 42. 4 ± 76. 30) vs.( 53. 86 ± 6. 55),the difference was statistically significant( P<0. 05),the standard-reaching rate of platelet aggregation rate of A group was higher than that of group B( 82. 26% vs.41. 94%),the difference was statistically significant( P<0. 05); MACE occurred rate 4 week after operation in Agroupwas lower than the control group( 12. 90% vs.30. 65%),the difference was statistically significant( P< 0. 05).Conclusion In patients with ACSafter PCI,ticagrelor is superior to clopidogrel in anti platelet aggregation and it can decrease the incidence rate of MACE event. |
Key words: acutecoronarysyndrome percutaneouscoronaryintervention ticagrelor clopidogrel |